

This Product Highlights Sheet is an important document.

- It highlights the key terms and risks of the ILP sub-fund and complements the Product Summary.
- It is important to read the Product Summary before deciding whether to purchase the ILP sub-fund. If you do not have a copy, please contact us to ask for one.
- You should not invest in the ILP sub-fund if you do not understand it or are not comfortable with the accompanying risks.

## R244 FPIL RobecoSAM Sustainable Healthy Living Equities (USD) (Invests in RobecoSAM Sustainable Healthy Living Equities D USD Acc)

<b>Product Type</b> (Specified Investment Product)	ILP Sub-Fund <sup>1</sup>	<b>Launch Date</b>	September 2021
<b>Management Company</b>	Robeco Institutional Asset Management B.V	<b>Custodian</b>	HSBC Plc
<b>Capital Guaranteed</b>	No	<b>Dealing Frequency</b>	Every UK Business Day
<b>Name of Guarantor</b>	N/A	<b>Expense Ratio for the underlying fund</b>	1.71% (as at 28/10/22)

### SUB-FUND SUITABILITY

#### WHO IS THE SUB-FUND SUITABLE FOR?

The Sub-Fund is suitable for Investors who want their investment to fully contribute to a sustainable investment objective. It is also suitable for informed and/or experienced Investors wishing to attain defined investment objectives and who can afford to set aside capital for at least 5-7 years. It can accommodate the investment objective of capital growth, income and/or portfolio diversification.

It is important to remember that, as with most investments, the value of your investments are not guaranteed and can go down as well as up. Therefore we suggest that you only invest money that can be committed for the medium to long term. You should also bear in mind that securities held within a fund may not be denominated in the currency of that fund, so unit prices may fall purely on account of exchange rate fluctuations.

Please note that Friends Provident International Limited ('FPIL') investment products are intended for medium to long term investment and are not therefore designed for early surrender. If you do surrender early, a product surrender charge may be applied. Please note that the earlier you terminate your plan, the more you may lose.

#### Further Information

-Refer to the section on 'Fees and Charges' in the relevant Product Summary.

-Refer to the 'Profile of the typical investor' section within 'Appendix I – Information Per Sub Fund' of the underlying fund's prospectus for further information on the suitability of the Sub-Fund.

### KEY FEATURES OF THE SUB-FUND

#### WHAT ARE YOU INVESTING IN?

You are investing in an ILP Sub-Fund that invests in RobecoSAM Sustainable Healthy Living Equities\* ('the Fund' or 'underlying fund'), apart from a proportionately small amount which may be held in cash to optimise dealing efficiencies in the underlying fund. We endeavour to maintain a cash balance limit of up to 0.75%.

The underlying fund of the ILP Sub-Fund is an accumulation fund, which means the fund will automatically reinvest any dividends.

\*The underlying Fund is a Sub-Fund of Robeco Capital Growth Funds. Robeco Capital Growth Funds is an Open-Ended Investment Company incorporated in Luxembourg and its home regulator is the Commission de Surveillance du Secteur Financier (CSSF).

-Refer to 'Section 1 – The Fund' of the underlying fund's prospectus for further information on the features of the Fund.

<sup>1</sup> For ILP Sub-Fund feeds 100% into an underlying fund, some information provided below could be similar to the underlying fund. In this instance this ILP sub-fund will be minimum feed 99.25% into the underlying fund, RobecoSAM Sustainable Healthy Living Equities Fund.

Investment Strategy	
<p>- The Fund has as its sustainable investment objective to promote good health and well-being and contribute to an efficient healthcare system in order to mitigate the rising incidence of lifestyle-driven chronic diseases and increasing healthcare costs, by investing in companies that provide technologies, products or services linked to the prevention of disease via eating healthier diets, exercising regularly and reducing the spread of infectious diseases with hygiene measures.</p> <p>-The Fund will take exposure of at least two thirds of its total assets to Equities of companies all over the world which operate or benefit from developments in technologies, products or services in the areas of healthy nutrition, health treatment, diagnosis and system efficiency, or physical activities, and good hygiene. This includes companies incorporated or having the major part of their business activities in mature economies (developed markets) as well as in developing economies (Emerging Markets) and which show an elevated degree of sustainability.</p> <p>-With due consideration given to the investment restrictions and to the extent permitted by the applicable legislation, the Sub-fund may invest in Equities, convertible bonds, bonds, units of UCITS and/or other UCIs and Derivatives to achieve the investment goals of the Sub-fund.</p> <p>-The Fund may also invest in money market instruments, bank deposits (other than deposits at sight) and other eligible liquid assets for treasury purposes and in case of unfavourable market conditions.</p> <p>-Exchange traded and over-the-counter Derivatives are permitted, including but not limited to futures, swaps and currency forwards. Whilst the Sub-fund may use Derivatives for Hedging and liquidity management (including the usage to manage currency and market exposures in a cost-effective manner), it does not intend to utilize Derivatives extensively for such purposes</p> <p>-For the purpose of gaining exposure to shares of companies of the People's Republic of China ("PRC") listed in China, the Sub-fund may invest up to 10% of its net assets in China A-Shares (via QFI and/or Stock Connect programmes) and China B-Shares issued by companies in the PRC and listed on PRC stock exchanges</p>	<p>-Refer to the Fund's section in 'Appendix I – Information Per Sub-Fund' section of the underlying fund's prospectus for further information on the investment strategy of the Fund.</p>
Parties Involved	
<p><b>WHO ARE YOU INVESTING WITH?</b></p> <p><b>Management Company of the underlying fund:</b> Robeco Institutional Asset Management B.V.</p> <p><b>Investment Manager of the underlying fund:</b> Robeco Schweiz AG</p> <p><b>Depository of the underlying fund:</b> JPMorgan SE, Luxembourg Branch</p>	<p>-Refer to 'Section 3' of the underlying fund's prospectus for further information on the roles and responsibilities of these entities and what happens if they become insolvent.</p>
KEY RISKS	
<p><b>WHAT ARE THE KEY RISKS OF THIS INVESTMENT?</b></p> <p>-The value of an investment is not guaranteed and can go up and down depending on performance. You could get back less than you have paid in. At times, the ILP Sub-Fund may (subject to the Appointed Actuary's agreement and provisions allowed for in the Policy Conditions) need to change the way its price is calculated, to ensure that those moving into and out of the ILP Sub-Fund are treated fairly. This can have a negative effect on the ILP Sub-Fund's price and performance.</p> <p>-Fund managers have the ability, in exceptional circumstances, to suspend trading in their funds for as long as necessary. When this occurs we will need to delay the 'cashing in' or switching of units in the relevant fund. You may not be able to access your money during this period.</p>	<p><b>Further Information</b></p> <p>-Refer to the 'Valuations and Pricing' section of your Policy Conditions.</p> <p>-Refer to 'Section 4 – Risk Considerations' of the underlying fund's prospectus for further information on the risks of the Fund.</p>

These risk factors may cause you to lose some or all of your investment:									
<b>Market and Credit Risks</b>									
<p><b>Investment Risks:</b> There is no guarantee that the Fund will achieve its objective. A capital loss of some or all of the amount invested may occur.</p> <p><b>Emerging Markets Risks:</b> In emerging and less developed markets the legal, judicial and regulatory infrastructure is still developing and there may be legal uncertainty both for local market participants and their overseas counterparts.</p> <p><b>Currency Risks:</b> All or part of the securities portfolio of the Fund may be invested in transferable securities, money market instruments, UCITS or other UCIs and other eligible financial instruments denominated in currencies other than the base currency of the Fund. As a result, fluctuations in the exchange rate may have both a negative and a positive effect on the investment result of the Fund.</p>									
<b>Liquidity Risks</b>									
<p><b>Liquidity risks:</b> There may be occasions when the manager is unable to sell some or all of the shares within the Fund, which could delay payment or redemption of proceeds.</p>									
<b>Product-Specific Risks</b>									
<p><b>Leverage Risks:</b> Financial derivative instruments may present a leverage effect, which will increase the Fund's sensitivity to market fluctuations. Given the leverage effect embedded in financial derivative instruments, such investments may result in higher Volatility or even a total loss of the Fund's assets within a short period of time</p> <p><b>Stock Connect Risks:</b> The Fund may invest and have direct access to certain eligible China A-Shares via the Shanghai-Hong Kong Stock Connect programme, and, as such, may be subject to additional risks.</p> <p><b>Sustainability Risks:</b> The Management Company systematically incorporates sustainability factors, to the extent these present a material risk to a Fund, into its investment and portfolio construction processes, alongside traditional financial risk factors.</p> <p><b>Concentration Risks:</b> Based on its investment policy, the Sub-Fund may invest in financial instruments from issuing institutions that (mainly) operate within the same sector or region, or on the same market. Due to the concentration of the investment portfolio of the Sub-Fund, events that have an effect on these issuing institutions may have a greater effect on the Sub-Fund's assets than in the case of a less concentrated investment portfolio.</p>									
<b>FEES AND CHARGES</b>									
<p><b>WHAT ARE THE FEES AND CHARGES OF THIS INVESTMENT?</b> Charges are deducted by both FPIL and the underlying investment managers at each valuation point before calculating the unit price, as set out below.</p> <p><b>FPIL charges (payable directly by you)</b> You will need to pay an ILP Sub-Fund administration charge of 1.2%. There is currently no charge for switching funds although switching to a fund which differs from your plan currency may involve a cost associated with currency exchange. However, we reserve the right to charge for switches under certain conditions. Any sales and/or redemption charges will be determined by the terms of your Policy Conditions.</p> <p><b>Underlying investment managers' charges (these charges are as at 28/10/2022 and are payable by the ILP Sub-Fund from invested proceeds)</b></p>	<p>-Refer to the section on 'Fees and Charges' in the relevant Product Summary.</p> <p>-Refer to the 'Charges' section of your Policy Conditions for further information.</p>								
<table border="1"> <tbody> <tr> <td>Annual Management Charge (AMC)</td> <td>1.50%</td> </tr> <tr> <td>Additional Expenses</td> <td>0.21%</td> </tr> <tr> <td>Expense Ratio</td> <td>1.71%</td> </tr> <tr> <td>Performance Fee</td> <td>Nil</td> </tr> </tbody> </table>	Annual Management Charge (AMC)	1.50%	Additional Expenses	0.21%	Expense Ratio	1.71%	Performance Fee	Nil	
Annual Management Charge (AMC)	1.50%								
Additional Expenses	0.21%								
Expense Ratio	1.71%								
Performance Fee	Nil								

**VALUATIONS AND EXITING FROM THIS INVESTMENT**
**HOW OFTEN ARE VALUATIONS AVAILABLE?**

Every UK Business Day

Latest fund prices can be obtained from <http://www.fpinternational.sg/fund-centre/>

**HOW CAN YOU EXIT FROM THIS INVESTMENT AND WHAT ARE THE RISKS AND COSTS IN DOING SO?**

There is a Cooling off period of 30 days from when you receive your Policy Documents. If you decide to exit the policy during this time you should complete the cancellation form and send this back to the address provided, together with the original Policy Documents. We will refund any monies paid, less any shortfall (if any) which may result if the value of your investment falls by the time you tell us of your wish to cancel. If you elect to exit your policy after the Cooling off period has expired, penalties may be applied.

If you no longer wish to invest in this FPIL ILP Sub-fund you have selected, you may switch all or part of your holdings into alternative fund(s) by sending us a completed Fund Transfer Request form, signed. Switching from one fund to another is done on a bid to bid basis, without charge (although we do reserve the right to charge). If you are switching between currencies, the relevant exchange rates will be applied and shown on your switch confirmation.

The sale proceeds that you will receive will be the realisation price multiplied by the number of units sold, less any charges. An example (assuming a redemption charge of 4%) is as follows \*:

Realisation price proceeds	Number of units sold	Gross Realisation
S\$0.93	x 100,000	= S\$93,000

Gross Realisation price proceeds	Realisation Fee	Net Realisation
S\$93,000	- S\$3,720	= S\$89,280

**Further Information**

-Refer to the 'Valuations and Pricing' section of your Policy Conditions for further information.

\*Refer to the section on 'Fees and Charges' in the relevant Product Summary.

**CONTACT INFORMATION**
**HOW DO YOU CONTACT US?**

For enquiries in relation to the Fund or any FPIL ILP Sub-Fund contact the Singapore representative at Friends Provident International Limited (Singapore Branch), 182 Cecil Street, Level 17 Frasers Tower, Singapore 069547, telephone number: (65) 6320 1088, email [singapore.enquiries@fpiom.com](mailto:singapore.enquiries@fpiom.com)

**APPENDIX : GLOSSARY OF TERMS**
**China A-Shares**

Shares issued by companies listed on the Shanghai or Shenzhen stock exchange and denominated in RMB.

**China B-Shares**

Shares issued by companies listed on the Shanghai or Shenzhen stock exchange and denominated in USD or HKD.

**Derivatives**

Financial Derivative Instruments (FDIs) are financial contracts whose value is tied to an underlying asset. Derivatives include futures and options.

**Emerging Markets**

Typically includes markets within countries that have an underdeveloped or developing infrastructure with significant potential for economic growth and increased capital market participation for foreign investors. These countries generally possess some of the following characteristics; recent economic liberalisation, debt ratings below investment grade, recent liberalisation of the political system and non-membership of the Organisation of Economic Cooperation and Development.

**Equities**

Ownership positions in companies that can be traded in public markets. Often produce current income which may

be paid in the form of dividends. In the event of the company going bankrupt equity holders' claims are subordinate to the claims of preferred stockholders and bondholders.

**Expense Ratio**

The Expense Ratio provides customers with an indication of the overall costs of investing in a particular fund. The Expense Ratio as calculated in accordance with the Investment Management Association of Singapore's guidelines on the disclosure of Expense Ratios. Different methods of calculation of Expense Ratio can be used, including Total Expense Ratio (TER) and Ongoing Charges Figure (OCF) but these are broadly the same.

**Hedge/Hedging**

Any transaction with the objective of limiting exposure to risk such as changes in exchange rates or prices.

**Ongoing Charges Figure (OCF)**

A type of Expense Ratio. The Ongoing Charges Figure is based on expenses for the previous year and is a ratio of the total ongoing charges to the fund's average net asset value over its last reporting period. This figure may vary from year to year. The charges you pay are used to pay the costs of the underlying ILP sub-fund, including the costs of marketing and distributing it. These charges reduce the potential growth of your investment.

For more information about charges, please consult the Prospectus for the underlying fund of the ILP sub-fund invested in, available from [www.fpinternational.sg/phs](http://www.fpinternational.sg/phs) Details of the calculation methodology can be found in full at: [www.esma.europa.eu/sites/default/files/library/2015/11/10\\_674.pdf](http://www.esma.europa.eu/sites/default/files/library/2015/11/10_674.pdf)

**Open-Ended Investment Company**

An open-ended collective investment vehicle, structured as an investment company, where new shares are created or redeemed, depending on demand from investors.

**Specified Investment Product (SIP)**

SIP is a class of investment products defined by the Monetary Authority of Singapore (MAS). Generally, (although not in all instances), financial advisers have to carry out more due diligence, including customer knowledge assessment, when advising about a SIP

**UCITS**

Undertaking for Collective investment in Transferable Securities. A type of collective investment (or fund) that allows financial institutions to operate freely throughout the European Union on the basis of a single authorisation from one member state.

**Volatility**

The relative rate at which the price of a security or fund moves up and down. Volatility is found by calculating the annualised standard deviation of daily change in price. If the price of a stock moves up and down rapidly over short time periods, it has high Volatility. If the price almost never changes, it has low Volatility.

Copyright © 2023 Friends Provident International Limited. All rights reserved.

Friends Provident International Limited: Registered and Head Office: Royal Court, Castletown, Isle of Man, British Isles, IM9 1RA. Telephone: +44 (0) 1624 821212 | Fax: +44 (0) 1624 824405 | Website: [www.fpinternational.com](http://www.fpinternational.com). Isle of Man incorporated company number 11494C. Authorised and regulated by the Isle of Man Financial Services Authority. Provider of life assurance and investment products. Authorised by the Prudential Regulation Authority. Subject to regulation by the Financial Conduct Authority and limited regulation by the Prudential Regulation Authority. Details about the extent of our regulation by the Prudential Regulation Authority are available from us on request. Singapore branch: 182 Cecil Street, Level 17 Frasers Tower, Singapore 069547. Telephone: +65 6320 1088 | Website: [www.fpinternational.sg](http://www.fpinternational.sg). Registered in Singapore No T06FC6835J. Licensed by the Monetary Authority of Singapore to conduct life insurance business in Singapore. Member of the Life Insurance Association of Singapore. Member of the Singapore Financial Dispute Resolution Scheme. Friends Provident International is a registered trademark and trading name of Friends Provident International Limited.